Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery (original) (raw)

• Rosenberg, S.A. & Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Gill, S. & June, C.H. Going viral: chimeric antigen receptor T cell therapy for hematological malignancies. Immunol. Rev. 263, 68–89 (2015).
  Article CAS PubMed Google Scholar
• Corrigan-Curay, J. et al. T cell immunotherapy: looking forward. Mol. Ther. 22, 1564–1574 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, L.A. et al. Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra22 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Klebanoff, C.A. et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 101, 1969–1974 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Wallace, A. et al. Transforming growth factor–β receptor blockade augments the effectiveness of adoptive T cell therapy of established solid cancers. Clin. Cancer Res. 14, 3966–3974 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Conlon, K.C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74–82 (2015).
  Article CAS PubMed Google Scholar
• Leonard, J.P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 90, 2541–2548 (1997).
  CAS PubMed Google Scholar
• Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278–2288 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, B. et al. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci. Transl. Med. 7, 291ra94 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Stephan, M.T., Moon, J.J., Um, S.H., Bershteyn, A. & Irvine, D.J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16, 1035–1041 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Stephan, M.T., Stephan, S.B., Bak, P., Chen, J. & Irvine, D.J. Synapse-directed delivery of immunomodulators using T cell–conjugated nanoparticles. Biomaterials 33, 5776–5787 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Ghezzi, P., Bonetto, V. & Fratelli, M. Thiol-disulfide balance: from the concept of oxidative stress to that of redox regulation. Antioxid. Redox Signal. 7, 964–972 (2005).
  Article CAS PubMed Google Scholar
• Lawrence, D.A., Song, R. & Weber, P. Surface thiols of human lymphocytes and their changes after in vitro and in vivo activation. J. Leukoc. Biol. 60, 611–618 (1996).
  Article CAS PubMed Google Scholar
• Berridge, M.V. & Tan, A.S. _Trans_-plasma membrane electron transport: a cellular assay for NADH- and NADPH-oxidase based on extracellular, superoxide-mediated reduction of the sulfonated tetrazolium salt WST-1. Protoplasma 205, 74–82 (1998).
  Article CAS Google Scholar
• Berridge, M.V. & Tan, A.S. Cell-surface NAD(P)H-oxidase: relationship to _trans_-plasma membrane NADH-oxidoreductase and a potential source of circulating NADH-oxidase. Antioxid. Redox Signal. 2, 277–288 (2000).
  Article CAS PubMed Google Scholar
• Riber, C.F., Smith, A.A. & Zelikin, A.N. Self-immolative linkers literally bridge disulfide chemistry and the realm of thiol-free drugs. Adv. Healthc. Mater. 4, 1887–1890 (2015).
  Article CAS PubMed Google Scholar
• Jones, L.R. et al. Releasable luciferin–transporter conjugates: tools for the real-time analysis of cellular uptake and release. J. Am. Chem. Soc. 128, 6526–6527 (2006).
  Article CAS PubMed Google Scholar
• Xu, J. et al. Rendering protein-based particles transiently insoluble for therapeutic applications. J. Am. Chem. Soc. 134, 8774–8777 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, X. et al. Novel human interleukin-15 agonists. J. Immunol. 183, 3598–3607 (2009).
  Article CAS PubMed Google Scholar
• Rhode, P.R. et al. Comparison of the superagonist complex, ALT-803, to IL-15 as cancer immunotherapeutics in animal models. Cancer Immunol. Res. 4, 49–60 (2016).
  Article CAS PubMed Google Scholar
• Yu, A., Olosz, F., Choi, C.Y. & Malek, T.R. Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common γ-chain and a lymphoid cell environment. J. Immunol. 165, 2556–2562 (2000).
  Article CAS PubMed Google Scholar
• Overwijk, W.W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569–580 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Maus, M.V. et al. Adoptive immunotherapy for cancer or viruses. Annu. Rev. Immunol. 32, 189–225 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Guo, Y. et al. IL-15 superagonist-mediated immunotoxicity: role of NK cells and IFN-γ. J. Immunol. 195, 2353–2364 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Patel, S.K., Zhang, Y., Pollock, J.A. & Janjic, J.M. Cyclooxgenase-2 inhibiting perfluoropoly (ethylene glycol) ether theranostic nanoemulsions–in vitro study. PLoS One 8, e55802 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Pradhan, D. & Morrow, J. The spectrin–ankyrin skeleton controls CD45 surface display and interleukin-2 production. Immunity 17, 303–315 (2002).
  Article CAS PubMed Google Scholar
• Chang, V.T. et al. Initiation of T cell signaling by CD45 segregation at 'close contacts'. Nat. Immunol. 17, 574–582 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, K.G., Bromley, S.K., Dustin, M.L. & Thomas, M.L. A supramolecular basis for CD45 tyrosine phosphatase regulation in sustained T cell activation. Proc. Natl. Acad. Sci. USA 97, 10138–10143 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, L. et al. Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines. Nanomedicine (Lond.) 10, 473–482 (2014).
  Article CAS Google Scholar
• Scott, E.A. et al. Protein adsorption and cell adhesion on nanoscale bioactive coatings formed from poly(ethylene glycol) and albumin microgels. Biomaterials 29, 4481–4493 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Tan, H. et al. PEG-urokinase nanogels with enhanced stability and controllable bioactivity. Soft Matter 8, 2644–2650 (2012).
  Article CAS Google Scholar
• Lin, X. et al. Oxidative stress in malignant melanoma enhances tumor necrosis factor–α secretion of tumor-associated macrophages that promote cancer cell invasion. Antioxid. Redox Signal. 19, 1337–1355 (2013).
  Article CAS PubMed Google Scholar
• Koshy, S.T., Ferrante, T.C., Lewin, S.A. & Mooney, D.J. Injectable, porous and cell-responsive gelatin cryogels. Biomaterials 35, 2477–2487 (2014).
  Article CAS PubMed Google Scholar
• Singh, N. et al. Bioresponsive mesoporous silica nanoparticles for triggered drug release. J. Am. Chem. Soc. 133, 19582–19585 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Au, K.M. et al. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: turning a bone anti-resorptive agent into an anticancer therapeutic. Biomaterials 82, 178–193 (2016).
  Article CAS PubMed Google Scholar
• Ling, D. et al. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano 8, 8027–8039 (2014).
  Article CAS PubMed Google Scholar
• Yang, Y. et al. Polymer nanoparticles modified with photo- and pH-dual-responsive polypeptides for enhanced and targeted cancer therapy. Mol. Pharm. 13, 1508–1519 (2016).
  Article CAS PubMed Google Scholar
• Chmielewski, M., Kopecky, C., Hombach, A.A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697–5706 (2011).
  Article CAS PubMed Google Scholar
• Chinnasamy, D. et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor 2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18, 1672–1683 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Pegram, H.J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Weinstein-Marom, H. et al. Membrane-attached cytokines expressed by mRNA electroporation act as potent T cell adjuvants. J. Immunother. 39, 60–70 (2016).
  Article CAS PubMed Google Scholar
• Desnoyers, L.R. et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci. Transl. Med. 5, 207ra144 (2013).
  Article PubMed CAS Google Scholar
• Wu, C.-Y., Roybal, K.T., Puchner, E.M., Onuffer, J. & Lim, W.A. Remote control of therapeutic T cells through a small-molecule-gated chimeric receptor. Science 350, aab4077 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Fedorov, V.D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5, 215ra172 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71–75 (2013).
  Article CAS PubMed Google Scholar
• Morgan, R.A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Han, K.P. et al. IL-15:IL-15 receptor–α superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56, 804–810 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zheng, Y. et al. In vivo targeting of adoptively transferred T cells with antibody- and cytokine-conjugated liposomes. J. Control. Release 172, 426–435 (2013).
  Article CAS PubMed PubMed Central Google Scholar